Misfolded proteins: From little villains to little helpers in the fight against cancer

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Brüning, Ansgar ^a   Jückstock, Julia ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aggresome; Autophagy; Bortezomib; Endoplasmic reticulum stress; HDAC6; Nelfinavir; Proteasome

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; DISULFIRAM; FLAVONOID; GANETESPIB; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; NELFINAVIR; PROTEASOME; PROTEASOME INHIBITOR; RADICICOL; RICOLINOSTAT;

AGGRESOME; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; HUMAN; HYPERTHERMIA; HYPERTHERMIC THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; PROTEIN HOMEOSTASIS; REVIEW; UBIQUITINATION;

EID: 84923606244     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00047     Document Type: Review

References (140)

1. Anfinsen CB. Principles that govern the folding of protein chains. Science (1973) 181(4096):223-30. doi: 10.1126/science.181.4096.223
2. Onuchic JN, Wolynes PG. Theory of protein folding. Curr Opin Struct Biol (2004) 14(1):70-5. doi:10.1016/j.sbi.2004.01.009
3. Contessoto VG, Lima DT, Oliveira RJ, Bruni AT, Chahine J, Leite VB. Analyzing the effect of homogeneous frustration in protein folding. Proteins (2013) 81(10):1727-37. doi:10.1002/prot.24309
4. Rose GD, Fleming PJ, Banavar JR, Maritan A. A backbone-based theory of protein folding. Proc Natl Acad Sci U S A (2006) 103(45):16623-33. doi:10.1073/pnas.0606843103
5. Tsai CJ, Maizel JV Jr, Nussinov R. The hydrophobic effect: a new insight from cold denaturation and a two-state water structure. Crit Rev Biochem Mol Biol (2002) 37(2):55-69. doi:10.1080/10409230290771456
6. Pace NC, Scholtz JM, Grimsley GR. Forces stabilizing proteins. FEBS Lett (2014) 588(14):2177-84. doi:10.1016/j.febslet.2014.05.006
7. Zhang G, Ignatova Z. Folding at the birth of the nascent chain: coordinating translation with co-translational folding. Curr Opin Struct Biol (2011) 21(1):25-31. doi:10.1016/j.sbi.2010.10.008
8. Wolff S, Weissman JS, Dillin A. Differential scales of protein quality control. Cell (2014) 157(1):52-64. doi:10.1016/j.cell.2014.03.007
9. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature (2003) 426(6968):895-9. doi:10.1038/nature02263
10. Garcia-Mata R, Gao YS, Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic (2002) 3(6):388-96. doi:10.1034/j.1600-0854.2002.30602.x
11. Bartlett AI, Radford SE. An expanding arsenal of experimental methods yields an explosion of insights into protein folding mechanisms. Nat Struct Mol Biol (2009) 16(6):582-8. doi:10.1038/nsmb.1592
12. Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem (2013) 82:323-55. doi:10.1146/annurev-biochem-060208-092442
13. Selkoe DJ. Folding proteins in fatal ways. Nature (2003) 426(6968):900-4. doi:10.1038/nature02264
14. Aigelsreiter A, Janig E, Stumptner C, Fuchsbichler A, Zatloukal K, Denk H. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases. Pathobiology (2007) 74(3):145-58. doi:10.1159/000103374
15. Gidalevitz T, Stevens F, Argon Y. Orchestration of secretory protein folding by ER chaperones. Biochem Biophys Acta (2013) 1833(11):2410-24. doi:10.1016/j.bbamcr.2013.03.007
16. Murphy ME. The HSP70 family and cancer. Carcinogenesis (2013) 34(6):1181-8. doi:10.1093/carcin/bgt111
17. Ellis RJ, Minton AP. Protein aggregation in crowded environments. Biol Chem (2006) 387:485-97. doi:10.1515/BC.2006.064
18. Lepock JR. Role of nuclear protein denaturation and aggregation in thermal radiosensitization. Int J Hyperthermia (2004) 20(2):115-30. doi:10.1080/02656730310001637334
19. Tompa P, Rose GD. The Levinthal paradox of the interactome. Protein Sci (2011) 20(12):2074-9. doi:10.1002/pro.747
20. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol (2010) 11(7):515-28. doi:10.1038/nrm2918
21. Miyata Y, Nakamoto H, Neckers L. The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des (2013) 19(3):347-65. doi:10.2174/1381612811306030347
22. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol (2013) 14(9):e358-69. doi:10.1016/S1470-2045(13)70169-4
23. Röhl A, Rohrberg J, Buchner J. The chaperone Hsp90: changing partners for demanding clients. Trends Biochem Sci (2013) 38(5):253-62. doi:10.1016/j.tibs.2013.02.003
24. Whitesell L, Lindquist S. Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin Ther Targets (2009) 13(4):469-78. doi:10.1517/14728220902832697
25. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta (2012) 1823(3):742-55. doi:10.1016/j.bbamcr.2011.10.008
26. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev (2013) 39(4):375-87. doi:10.1016/j.ctrv.2012.10.001
27. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Psaltopoulou T. Hsp90 inhibitors in breast cancer: a systematic review. Breast (2013) 22(5):569-78. doi:10.1016/j.breast.2013.06.003
28. Zhou D, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, et al. A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors. Toxicol Appl Pharmacol (2013) 273:401-9. doi:10.1016/j.taap.2013.09.018
29. Li J, Buchner J. Structure, function and regulation of the hsp90 machinery. Biomed J (2013) 36(3):106-17. doi:10.4103/2319-4170.113230
30. Hernández MP, Sullivan WP, Toft DO. The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J Biol Chem (2002) 277(41):38294-304. doi:10.1074/jbc.M206566200
31. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci (2005) 62(6):670-84. doi:10.1007/s00018-004-4464-6
32. Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol (2012) 22(8):407-17. doi:10.1016/j.tcb.2012.05.006
33. Benbrook DM, Long A. Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. Exp Oncol (2012) 34(3):286-97.
34. McDonough H, Patterson C. CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones (2003) 8(4):303-8. doi:10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2
35. Stankiewicz M, Nikolay R, Rybin V, Mayer MP. CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates. FEBS J (2010) 277(16):3353-67. doi:10.1111/j.1742-4658.2010.07737.x
36. Daugaard M, Rohde M, Jäättelä M. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett (2007) 581(19):3702-10. doi:10.1016/j.febslet.2007.05.039
37. de Thonel A, Le Mouël A, Mezger V. Transcriptional regulation of small HSP-HSF1 and beyond. Int J Biochem Cell Biol (2012) 44(10):1593-612. doi:10.1016/j.biocel.2012.06.012
38. Beere HM. 'The stress of dying': the role of heat shock proteins in the regulation of apoptosis. J Cell Sci (2004) 117:2641-51. doi:10.1242/jcs.01284
39. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, et al. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell (2012) 150(3):549-62. doi:10.1016/j.cell.2012.06.031
40. Kumar S, Tomar MS, Acharya A. HSF1-mediated regulation of tumor cell apoptosis: a novel target for cancer therapeutics. Future Oncol (2013) 9(10):1573-86. doi:10.2217/fon.13.106
41. Akerfelt M, Morimoto RI, Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. Nat Rev Mol Cell Biol (2010) 11:545-55. doi:10.1038/nrm2938
42. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RL, Workman P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle (2010) 9(8):1542-50. doi:10.4161/cc.9.8.11204
43. McConnell JR, McAlpine SR. Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett (2013) 23(7):1923-8. doi:10.1016/j.bmcl.2013.02.014
44. Zhang L, Fok JH, Davies FE. Heat shock proteins in multiple myeloma. Oncotarget (2014) 5(5):1132-48.
45. Hosokawa N, Hirayoshi K, Kudo H, Takechi H, Aoike A, Kawai K, et al. Inhibition of the activation of heat shock factor in vivo and in vitro by flavonoids. Mol Cell Biol (1992) 12(8):3490-8.
46. Elia G, Santoro MG. Regulation of heat shock protein synthesis by quercetin in human erythroleukaemia cells. Biochem J (1994) 300:201-9.
47. Nagai N, Nakai A, Nagata K. Quercetin suppresses heat shock response by down regulation of HSF1. Biochem Biophys Res Commun (1995) 208(3):1099-105. doi:10.1006/bbrc.1995.1447
48. Aalinkeel R, Bindukumar B, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, et al. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate (2008) 68:1773-89. doi:10.1002/pros.20845
49. Bruning A. Inhibition of mTOR signaling by quercetin in cancer treatment and prevention. Anticancer Agents Med Chem (2013) 13(7):1025-31. doi:10.2174/18715206113139990114
50. Heimberger T, Andrulis M, Riedel S, Stühmer T, Schraud H, Beilhack A, et al. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol (2013) 160(4):465-76. doi:10.1111/bjh.12164
51. Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, et al. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget (2013) 4(6):816-29.
52. Wang G, Gao Y, Li L, Jin G, Cai Z, Chao JI, et al. K63-linked ubiquitination in kinase activation and cancer. Front Oncol (2012) 2:5. doi:10.3389/fonc.2012.00005
53. Johnson DE. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer (2015) 22(1):T1-17. doi:10.1530/ERC-14-0005
54. Ciechanover A, Stanhill A. The complexity of recognition of ubiquitinated substrates by the 26S proteasome. Biochim Biophys Acta (2014) 1843(1):86-96. doi:10.1016/j.bbamcr.2013.07.007
55. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer (2004) 4(5):349-60. doi:10.1038/nrc1361
56. Shabek N, Ciechanover A. Degradation of ubiquitin: the fate of the cellular reaper. Cell Cycle (2010) 9(3):523-30. doi:10.4161/cc.9.3.11152
57. Navon A, Ciechanover A. The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem (2009) 284(49):33713-8. doi:10.1074/jbc.R109.018481
58. Yamaguchi H, Hsu JL, Hung MC. Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Front Oncol (2012) 2:15. doi:10.3389/fonc.2012.00015
59. Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC. Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol (2014) 21(4):e573-603. doi:10.3747/co.21.1798
60. Skrott Z, Cvek B. Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. Crit Rev Oncol Hematol (2014) 92(2):61-70. doi:10.1016/j.critrevonc.2014.05.003
61. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 19(1):99-115. doi:10.1016/j.chembiol.2012.01.003
62. Crawford LJ, Irvine AE. Targeting the ubiquitin proteasome system in haematological malignancies. Blood Rev (2013) 27(6):297-304. doi:10.1016/j.blre.2013.10.002
63. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood (2006) 107:4907-16. doi:10.1182/blood-2005-08-3531
64. Brüning A, Burger P, Vogel M, Rahmeh M, Friese K, Lenhard M, et al. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Invest New Drugs (2009) 27(6):543-51. doi:10.1007/s10637-008-9206-4
65. Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors-molecular basis and current perspectives in multiple myeloma. J Cell Mol Med (2014) 18(6):947-61. doi:10.1111/jcmm.12279
66. Kordower JH, Kanaan NM, Chu Y, Suresh Babu R, Stansell J III, Terpstra BT, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol (2006) 60(2):264-8. doi:10.1002/ana.20935
67. Redic K. Carfilzomib: a novel agent for multiple myeloma. J Pharm Pharmacol (2013) 65(8):1095-106. doi:10.1111/jphp.12072
68. Thompson JL. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann Pharmacother (2013) 47(1):56-62. doi:10.1345/aph.1R561
69. Allegra A, Alonci A, Gerace D, Russo S, Innao V, Calabrò L, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res (2014) 38(1):1-9. doi:10.1016/j.leukres.2013.10.018
70. Chang TL. Inhibitory effect of flavonoids on 26S proteasome activity. J Agric Food Chem (2009) 57:9706-15. doi:10.1021/jf9017492
71. Klappan AK, Hones S, Mylonas I, Brüning A. Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity. Histochem Cell Biol (2012) 137(1):25-36. doi:10.1007/s00418-011-0869-0
72. Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol (2012) 83:6-15. doi:10.1016/j.bcp.2011.08.010
73. Jia L, Liu FT. Why bortezomib cannot go with 'green'? Cancer Biol Med (2013) 10(4):206-13. doi:10.7497/j.issn.2095-3941.2013.04.004
74. Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, et al. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma (2013) 54(9):1996-2002. doi:10.3109/10428194.2012.760733
75. Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol (2011) 153:729-40. doi:10.1111/j.1365-2141.2011.08664.x
76. Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, et al. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs (2013) 31(5):1251-6. doi:10.1007/s10637-013-9946-7
77. Lövborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, Larsson R. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer (2006) 118(6):1577-80. doi:10.1002/ijc.21534
78. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res (2006) 66(21):10425-33. doi:10.1158/0008-5472.CAN-06-2126
79. Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the international initiative for accelerated improvement of glioblastoma care. Oncotarget (2013) 4(4):502-30.
80. Papaioannou M, Mylonas I, Kast RE, Brüning A. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition. Oncoscience (2014) 1:21-9.
81. Brüning A, Kast RE. Oxidizing to death: disulfiram for cancer cell killing. Cell Cycle (2014) 13(10):1513-4. doi:10.4161/cc.28959
82. Kona FR, Buac D, Burger MA. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies. Curr Cancer Drug Targets (2011) 11(3):338-46. doi:10.2174/156800911794519798
83. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol (2000) 10(12):524-30. doi:10.1016/S0962-8924(00)01852-3
84. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell (2003) 115(6):727-38. doi:10.1016/S0092-8674(03)00939-5
85. Ouyang H, Ali YO, Ravichandran M, Dong A, Qiu W, MacKenzie F, et al. Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. J Biol Chem (2012) 287(4):2317-27. doi:10.1074/jbc.M111.273730
86. Chin LS, Olzmann JA, Li L. Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochem Soc Trans (2010) 38:144-9. doi:10.1042/BST0380144
87. Hao R, Nanduri P, Rao Y, Panichelli RS, Ito A, Yoshida M, et al. Proteasomes activate aggresome disassembly and clearance by producing unanchored ubiquitin chains. Mol Cell (2013) 51(6):819-28. doi:10.1016/j.molcel.2013.08.016
88. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J (2010) 29(5):969-80. doi:10.1038/emboj.2009.405
89. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 280(29):26729-34. doi:10.1074/jbc.C500186200
90. Kovacs JJ, Cohen TJ, Yao TP. Chaperoning steroid hormone signaling via reversible acetylation. Nucl Recept Signal (2005) 3:e004. doi:10.1621/nrs.03004
91. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev (2007) 21(17):2172-81. doi:10.1101/gad.436407
92. Ye Y, Meyer HH, Rapoport TA. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature (2001) 414(6864):652-6. doi:10.1038/414652a
93. Yamanaka K, Sasagawa Y, Ogura T. Recent advances in p97/VCP/Cdc48 cellular functions. Biochim Biophys Acta (2012) 1823(1):130-7. doi:10.1016/j.bbamcr.2011.07.001
94. Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol (2012) 14(2):117-23. doi:10.1038/ncb2407
95. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W, et al. HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J (2006) 25(14):3357-66. doi:10.1038/sj.emboj.7601210
96. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol (2011) 2011:875824. doi:10.1155/2011/875824
97. Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol (2008) 10(7):395-8. doi:10.1007/s12094-008-0221-x
98. Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs (2014) 25(2):140-9. doi:10.1097/CAD.0000000000000040
99. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A (2003) 100(8):4389-94. doi:10.1073/pnas.0430973100
100. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 102(24):8567-72. doi:10.1073/pnas.0503221102
101. Aldana-Masangkay GI, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Hsieh YT, Kim YM, et al. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk Lymphoma (2011) 52(8):1544-55. doi:10.3109/10428194.2011.570821
102. Namdar M, Perez G, Ngo L, Marks PA. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A (2010) 107(46):20003-8. doi:10.1073/pnas.1013754107
103. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc (2010) 132(31):10842-6. doi:10.1021/ja102758v
104. Zhang L, Liu C, Wu J, Tao JJ, Sui XL, Yao ZG, et al. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice. J Alzheimers Dis (2014) 41(4):1193-205. doi:10.3233/JAD-140066
105. Rosik L, Niegisch G, Fischer U, Jung M, Schulz WA, Hoffmann MJ. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biol Ther (2014) 15(6):742-57. doi:10.4161/cbt.28469
106. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood (2012) 119(11):2579-89. doi:10.1182/blood-2011-10-387365
107. Rapoport TA. Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature (2007) 450:663-9. doi:10.1038/nature06384
108. Braakman I, Bulleid NJ. Protein folding and modification in the mammalian endoplasmic reticulum. Annu Rev Biochem (2011) 80:71-99. doi:10.1146/annurev-biochem-062209-093836
109. Swanton E, Bulleid NJ. Protein folding and translocation across the endoplasmic reticulum membrane. Mol Membr Biol (2003) 20(2):99-104. doi:10.1080/0968768031000069241
110. Buchberger A, Bukau B, Sommer T. Protein quality control in the cytosol and the endoplasmic reticulum: brothers in arms. Mol Cell (2010) 40(2):238-52. doi:10.1016/j.molcel.2010.10.001
111. Smith MH, Ploegh HL, Weissman JS. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science (2011) 334(6059):1086-90. doi:10.1126/science.1209235
112. Olzmann JA, Kopito RR, Christianson JC. The mammalian endoplasmic reticulum-associated degradation system. Cold Spring Harb Perspect Biol (2013) 5(9):a013185. doi:10.1101/cshperspect.a013185
113. Strasser A, Puthalakath H. Fold up or perish: unfolded protein response and chemotherapy. Cell Death Differ (2008) 15(2):223-5. doi:10.1038/sj.cdd.4402279
114. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol (2009) 625(1-3):234-46. doi:10.1016/j.ejphar.2009.06.064
115. Gorman AM, Healy SJ, Jäger R, Samali A. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol Ther (2012) 134(3):306-16. doi:10.1016/j.pharmthera.2012.02.003
116. Schönthal AH. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol (2013) 85(5):653-66. doi:10.1016/j.bcp.2012.09.012
117. Cebollero E, Reggiori F, Kraft C. Reticulophagy and ribophagy: regulated degradation of protein production factories. Int J Cell Biol (2012) 2012:182834. doi:10.1155/2012/182834
118. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol (2011) 13(3):184-90. doi:10.1038/ncb0311-184
119. Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta (2013) 1833(12):3460-70. doi:10.1016/j.bbamcr.2013.06.028
120. Urra H, Dufey E, Lisbona F, Rojas-Rivera D, Hetz C. When ER stress reaches a dead end. Biochim Biophys Acta (2013) 1833(12):3507-17. doi:10.1016/j.bbamcr.2013.07.024
121. Djedaini M, Peraldi P, Drici MD, Darini C, Saint-Marc P, Dani C, et al. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun (2009) 386:96-100. doi:10.1016/j.bbrc.2009.05.148
122. Wu X, Sun L, Zha W, Studer E, Gurley E, Chen L, et al. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology (2010) 138:197-209. doi:10.1053/j.gastro.2009.08.054
123. Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, et al. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway. Free Radic Biol Med (2013) 65:778-88. doi:10.1016/j.freeradbiomed.2013.08.161
124. Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia (2007) 9(4):271-8. doi:10.1593/neo.07124
125. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 13(17):5183-94. doi:10.1158/1078-0432.CCR-07-0161
126. Pyrko P, Kardosh A, Wang W, Xiong W, Schönthal AH, Chen TC. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res (2007) 67(22):10920-8. doi:10.1158/0008-5472.CAN-07-0796
127. McLean K, VanDeVen NA, Sorenson DR, Daudi S, Liu JR. The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells. Gynecol Oncol (2009) 112(3):623-30. doi:10.1016/j.ygyno.2008.11.028
128. Brüning A, Gingelmaier A, Friese K, Mylonas I. New prospects for nelfinavir in non-HIV-related diseases. Curr Mol Pharmacol (2010) 3(2):91-7. doi:10.2174/1874-470211003020091
129. Brüning A, Vogel M, Mylonas I, Friese K, Burges A. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets (2011) 11(7):799-809. doi:10.2174/156800911796798913
130. Fiebiger E, Hirsch C, Vyas JM, Gordon E, Ploegh HL, Tortorella D. Dissection of the dislocation pathway for type I membrane proteins with a new small molecule inhibitor, eeyarestatin. Mol Biol Cell (2004) 15(4):1635-46. doi:10.1091/mbc.E03-07-0506
131. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T, et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A (2009) 106(7):2200-5. doi:10.1073/pnas.0807611106
132. Brem GJ, Mylonas I, Brüning A. Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression. Gynecol Oncol (2013) 128(2):383-90. doi:10.1016/j.ygyno.2012.10.021
133. Valle CW, Min T, Bodas M, Mazur S, Begum S, Tang D, et al. Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS One (2011) 6(12):e29073. doi:10.1371/journal.pone.0029073
134. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol (2002) 3(8):487-97. doi:10.1016/S1470-2045(02)00818-5
135. Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer (2008) 44(17):2546-54. doi:10.1016/j.ejca.2008.07.038
136. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol (2002) 43(1):33-56. doi:10.1016/S1040-8428(01)00179-2
137. Roti Roti JL. Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events. Int J Hyperthermia (2008) 24(1):3-15. doi:10.1080/02656730701769841
138. Harmon BV, Corder AM, Collins RJ, Gobé GC, Allen J, Allan DJ, et al. Cell death induced in a murine mastocytoma by 42-47 degrees C heating in vitro: evidence that the form of death changes from apoptosis to necrosis above a critical heat load. Int J Radiat Biol (1990) 58(5):845-58. doi:10.1080/09553009014552221
139. Multhoff G. Activation of natural killer cells by heat shock protein 70. Int J Hyperthermia (2009) 25(3):169-75. doi:10.1080/02656730902902001
140. Blumenthal GM, Gills JJ, Ballas MS, Bernstein WB, Komiya T, Dechowdhury R, et al. A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. Oncotarget (2014) 5(18):8161-72.